Laboratory Autoclave Patents: Leaders, Trends & White Space 2026
- Concentrated at the top. the five most active filers account for 52.7% of all 582 records in scope, and the leader alone holds 133.
- Filing has cooled sharply. activity peaked at 33 records in 2021 and fell to 2 by 2024, a 94% drop over that span.
- Sterilising claims dominate. A61L covers 64.4% of records, while adjacent classes like healthcare informatics (G16H, 2.7%) remain thin.
Filing growth compares 2021 (33 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 582 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks 582 published patent families filed against laboratory autoclaves, steam sterilizers and laboratory waste sterilization systems, filtered to records that also address cycle validation, load configuration, effluent decontamination, door interlocks, water consumption or biological indicators. The scope spans 2015 through mid-2026, capturing both the equipment side (chamber design, interlocks, water use) and the verification side (biological indicators, cycle validation) that together define how a sterilization claim is built and defended.
Because publication trails filing by roughly 18 months, the most recent one to two years in any trend understate real activity; treat 2024 as the last complete filing year and read 2025-2026 as still filling in.
Filing trends and technology composition
Two views of the same 582-record set: how filing volume has moved year over year, and how those records distribute across IPC subclasses.
Filing trend: a sharp rise and a sharper pullback
Filings rose from 6 in 2017 to a peak of 33 in 2021, then fell to 2 by 2024 — a 94% decline across that three-year window. Given the ~18-month publication lag, 2025 and 2026 figures will rise as later filings publish, but the peak-to-2024 contraction itself is the reliable read.
Technology composition: sterilising claims dominate, informatics lags
A61L (sterilising and disinfecting) touches 64.4% of the 582 records, followed by C12Q (enzyme/DNA-based testing, 29.6%) and G01N (material analysis and testing, 25.8%). Records can carry multiple IPC classes, so these shares sum past 100%; healthcare informatics (G16H) and microorganism/genetic engineering (C12N) sit at the thin end, at 2.7% and 3.1% respectively.
Shares are the percentage of the 582 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Laboratory Autoclaves and Waste Sterilization with Eureka
This page is one run against one query. Ask Eureka your own question about laboratory autoclaves and waste sterilization and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this field
Process challenge device for a high-pressure steam sterilizer and sheet for a challenge device
A reusable process challenge device for a high-pressure steam sterilizer built from stacked, steam-permeable layers that house a sterilization indicator, aimed at reducing the trouble associated with single-use challenge devices.Filed by Sakura Color Products Corporation, published 2007-11-15 as US20070264683A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6884392B2 | Apparatus and method for steam reprocessing flexible endoscopes | 1,074 |
| 2 | US5073488A | Rapid method for determining efficacy of a sterilization cycle and rapid read-out biological indicator | 305 |
| 3 | US5418167A | Rapid read-out biological indicator | 221 |
| 4 | US5223401A | Rapid read-out sterility indicator | 202 |
| 5 | US5739004A | Biological sterilization indication for use with or without test pack materials or devices | 155 |
| 6 | US4670227A | Apparatus and method for handling of infectious waste material | 149 |
| 7 | US6485979B1 | Electronic system for tracking and monitoring articles to be sterilized and associated method | 147 |
| 8 | US6488890B1 | Machine readable sterilization indicator for monitoring articles to be sterilized | 126 |
| 9 | US5252484A | Rapid read-out biological indicator | 126 |
| 10 | US20040091389A1 | Apparataus and method for steam reprocessing flexible endoscopes | 118 |
Citation counts favour older records inside a searched corpus and should be read as a signal of influence, not current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the ranking, trend and IPC data are read together.
A small group holds half the field
The five most active assignees account for 52.7% of all 582 records in scope, with the leader alone at 133 — well ahead of the fifth-place holder at 18. That gap between first and fifth suggests one or two entities set the pace on core cycle-validation and indicator claims, while the rest of the top group files at a materially lower rate.
Activity has pulled back hard from its 2021 peak
Filings rose steadily to a peak of 33 in 2021, then dropped to 2 by 2024 — a 94% contraction over three years. That decline lands in years that are past the ~18-month publication lag, so it reflects a genuine slowdown in completed filings rather than an artefact of recent under-reporting.
Sterilising claims crowd the core, informatics stays open
A61L (sterilising and disinfecting) appears in 64.4% of the 582 records, making chamber- and cycle-level claims the densest part of the field. G16H (healthcare informatics, 2.7%) and C12N (microorganisms and genetic engineering, 3.1%) are comparatively open, pointing to where digital cycle-tracking or biological-marker claims face less prior art.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to laboratory autoclaves and waste sterilization, with the prior art for and against each one.
Who is filing, and where the activity has gone quiet
The ranked leaders combine established sterilization-equipment manufacturers with biological-indicator specialists; recent-year momentum has flattened across nearly all of them.
One assignee sets the pace on volume
The top-ranked assignee holds 133 of the 582 records in scope, more than seven times the fifth-place holder's 18. That gap indicates a filer with a long-running program across both equipment and indicator claims rather than a single product push.
A second tier files steadily but far behind
Fifth place sits at 18 records and tenth place at 12 — a much flatter curve than the gap to the leader. Combined, the top 10 account for 65.5% of all 582 records, meaning the remaining ranked companies split the last third among a much longer tail.
Momentum has gone flat across the board
Several of the assignees tracked for recent-year momentum, including established sterilization and biotech names, show zero filings in the latest year, with at least one recording a -100% year-on-year change. This pattern is consistent with the broader post-2021 pullback rather than isolated to one company.
| Assignee | Recent year | YoY |
|---|---|---|
| 3M Innovative Properties Co. | 0 | — |
| 3M Company | 0 | — |
| American Sterilizer Company (Steris) | 0 | -100% |
| Sage Therapeutics, Inc. | 0 | — |
| Getinge Sterilization AB | 0 | — |
| AOBiome LLC | 0 | — |
| Propper Manufacturing Co., Inc. | 0 | — |
| Ethicon, Inc. | 0 | — |
Where to take this from here
The dataset points to where claim space is dense and where it is thin; the next step is testing a specific claim or design against it.
Check freedom-to-operate on a specific cycle-validation claim
Run a candidate claim against the most-cited records in this set, particularly the biological-indicator patents that carry the heaviest citation weight.
Explore in Patsnap EurekaTrack the leader's recent filing behaviour
With top-tier momentum flat across nearly all tracked assignees, watch for the next filing wave rather than assuming continued decline.
Explore in Patsnap EurekaScope a white-space filing in informatics or genetic assays
G16H and C12N remain thin relative to the sterilising core, making them candidates for a first claim rather than a crowded one.
Explore in Patsnap EurekaCommon questions about this landscape
The ranking returned for this dataset covers 100 companies, and it is concentrated at the top: the leading assignee holds 133 of the 582 records in scope, well ahead of the fifth-place holder at 18. The top five combined account for 52.7% of all records, and the top ten reach 65.5%. This means a small number of filers, mostly established sterilization-equipment manufacturers and biological-indicator specialists, control a majority of the documented claim space, while the remaining ranked companies file at a much lower and flatter rate.
Filing activity peaked at 33 records in 2021 and had fallen to 2 by 2024, a 94% decline over that three-year span. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are still incomplete and should not be read as confirming further decline, but the 2021-to-2024 contraction itself is based on complete years and is a real pullback. Anyone benchmarking current activity should treat the post-2021 peak as the relevant baseline rather than the raw yearly totals for the last one to two years.
Sterilising and disinfecting claims under IPC class A61L appear in 64.4% of the 582 records, making it by far the densest part of the field. Testing-related classes follow: C12Q (enzyme and DNA-based measuring, 29.6%) and G01N (material analysis and testing, 25.8%). Because a single record can carry multiple IPC classes, these shares add up to more than 100%, and they should be read as coverage rates against the full record set rather than as mutually exclusive categories.
The classes with the lowest coverage relative to the sterilising core are healthcare informatics (G16H, at 2.7% of records) and microorganism and genetic engineering (C12N, at 3.1%). Bioreactor and enzyme-apparatus claims (C12M, 10.5%) and medicinal-preparation claims (A61K, 8.6%) also sit well below the core sterilising and testing classes. These lower-density branches are reasonable starting points for a first claim, since they carry less accumulated prior art than the chamber- and cycle-level claims that dominate the field.
US20070264683A1 describes a reusable process challenge device for high-pressure steam sterilizers built from stacked steam-permeable layers housing an indicator, filed by Sakura Color Products Corporation and published in 2007. It is a representative record in this dataset rather than the most-cited one, so its practical blocking effect depends on how closely a new design's challenge-device construction matches the specific stacked-layer, steam-permeable-body arrangement it describes. Any freedom-to-operate check should compare the exact claim language against the layered structure described here rather than assuming broad coverage of all process challenge devices.
Research Laboratory Autoclaves and Waste Sterilization in depth with Eureka
Go past this page: query the whole laboratory autoclaves and waste sterilization corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.